“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.
You may also be interested in...
PhRMA, Sen. Grassley Dispute Over “Whistleblower” Law Wanes
Finance Chairman says the latest letter from the trade group regarding efforts to prevent fraudulent drug pricing and billing practices is more encouraging than their initial exchange. PhRMA says it will be in touch with committee staff to further discuss False Claims Act issues.
PhRMA, Sen. Grassley Dispute Over “Whistleblower” Law Wanes
Finance Chairman says the latest letter from the trade group regarding efforts to prevent fraudulent drug pricing and billing practices is more encouraging than their initial exchange. PhRMA says it will be in touch with committee staff to further discuss False Claims Act issues.
Sen. Grassley Rejects PhRMA's Complaints About "Whistleblower" Law
In letters to PhRMA and the HHS Inspector General, finance chief rebukes trade association for being "out of tune" with its members on the False Claims Act. PhRMA asserts the FCA "stacks the deck" against drug makers in litigation and discourages internal complaints.